Source: Annual Congress 2005 - Pulmonary thromboembolic disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. J. Snijder, R. H. Heijmen, H. W. Plokker, W. J. Morshuis (Nieuwegein, Netherlands). Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH). Eur Respir J 2005; 26: Suppl. 49, 1832

Member's Comments

No comment yet.

Related content which might interest you: Bosentan for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients after pulmonary embolism Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy? Source: Annual Congress 2005 - News about pulmonary embolism Year: 2005 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients. Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012